Beam Therapeutics Inc. (BEAM) earnings
BEAM earnings moved a median of -0.90% by the close. Quarterly and annual BEAM reports and results, each read against the price at its own news timestamp. Back to the BEAM overview →
22 measured BEAM earnings events.
Where these BEAM earnings landedvs 22 measured BEAM earnings reactions
| Middle 50% of BEAM earnings reactions | -1.79% to +4.56% |
|---|---|
| Median reaction (to close) | -0.90% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 BEAM earnings events with a measured close landed between -1.79% and +4.56%; 32% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Press release | +0.43% | +6.06% | |
| Form 10-Q Beam Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.43% | +6.06% | |
| Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates | Press release | +1.42% | -0.79% | |
| Form 10-Q Beam Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.42% | -0.79% | |
| Form 10-K Beam Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | +3.63% | +8.54% | |
| Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates | Press release | +1.49% | -1.64% | |
| Form 10-Q Beam Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.49% | -1.64% | |
| Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | Press release | -3.99% | -1.79% | |
| Form 10-Q Beam Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.99% | -1.79% | |
| Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | Press release | -4.35% | -17.15% | |
| Form 10-Q Beam Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | -4.35% | -17.15% | |
| Form 10-K Beam Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | -0.84% | -7.04% | |
| Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs | Press release | +3.39% | +11.46% | |
| Form 10-Q Beam Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | +3.39% | +11.46% | |
| Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting | Press release | -0.27% | +0.04% | |
| Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results | Press release | -3.86% | -0.51% | |
| Form 10-Q Beam Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.86% | -0.51% | |
| Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results | Press release | -1.01% | -1.01% | |
| Form 10-Q Beam Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.01% | -1.01% | |
| Form 10-K Beam Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | -1.84% | +13.38% | |
| Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results | Press release | -3.48% | -7.33% | |
| Form 10-Q Beam Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.48% | -7.33% |
Keep exploring
More BEAM: analyst actions → · SEC filings → · BEAM overview →